Axogen Reports Q4 Revenue of $59.9M
Reports Q4 revenue $59.9M, consensus $59.9M. "2025 was a remarkable year of financial and operational achievement for Axogen, as we attained or progressed every objective expected of our strategic plan. With the FDA's approval of our Biologics License Application for Avance as the only implantable biologic indicated for treatment of peripheral nerve discontinuities, and the continued demonstration of the effectiveness and predictability of our market development strategies, we are confident we have a foundation for future growth and advancement of our mission to make restoration of peripheral function a standard of care," commented Michael Dale, President and CEO of Axogen, Inc. "Importantly for shareholders, we exited 2025 financially stronger and positioned to continue our important work profitably while generating positive cash flow."
